Jiangsu Yahong Initiates Phase III Study for Hexvix in Bladder Cancer Detection
China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has announced the...
China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has announced the...
US-based Acorda Therapeutics Inc. (Nasdaq: ACOR) announced a licensing agreement with China’s Asieris Pharmaceuticals for...